TCM
URGN icon

TCG Crossover Management’s UroGen Pharma URGN Stock Holding History

TCG Crossover Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.29M Sell
405,365
-311,982
-43% -$6.25M 0.21% 41
2025
Q4 		$16.8M Hold
717,347
– – 0.56% 34
2025
Q3 		$14.3M Buy
+717,347
New +$12.9M 0.7% 29

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

TCG Crossover Management's URGN Position: Q1 2026 in Review

TCG Crossover Management reduced its UroGen Pharma (URGN) stake by 43% in Q1 2026, selling an estimated $6.25M and leaving 405,365 shares worth $7.29M. The position accounts for 0.21% of the portfolio, ranked #41.

TCG Crossover Management first reported a position in URGN in Q3 2025 and has held it in 3 quarters since. The position peaked at $16.8M in Q4 2025. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • TCG Crossover Management held 405,365 shares of UroGen Pharma worth $7.29M as of Q1 2026.
  • TCG Crossover Management sold 311,982 UroGen Pharma shares in Q1 2026, an estimated $6.25M.
  • UroGen Pharma made up 0.21% of TCG Crossover Management's portfolio in Q1 2026, its #41 holding.
  • TCG Crossover Management first reported a position in UroGen Pharma in Q3 2025 and has held it in 3 quarters since.
  • TCG Crossover Management's UroGen Pharma position peaked at $16.8M in Q4 2025.
  • 172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.